Amicus Therapeutics — Investor Presentation (September 2022)
31 slides from Amicus Therapeutics's investor presentation, Sep 14, 2022
Slide 1: Corporate Overview September 2022
Corporate Overview September 2022 At the Forefront of Therapies for Rare Diseases
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies
Slide 3: A Rare Company
3 A Rare Company Patient - dedicated, Rare Disease Biotechnology Company with Sustained Double - digit Revenue Growth, a Global Commercial Infrastructure, and Late - stage Development Capabilities AT - GAA a Two - component Therapy Under Global Regulatory Reviews for Pompe Disease GLOBAL COMMERCIAL
Slide 4: 2022 Strategic Priorities to Drive Value
2022 Strategic Priorities to Drive Value 1 2 3 4 5 Double - digit Galafold growth (15 - 20%) with revenue of $350M to $365M at CER 1 Secure FDA approval and positive CHMP opinion for AT - GAA Initiate successful, rapid launch in U.S. for AT - GAA Advance best - in - class, next - generation genetic
Slide 5: Amicus Pipeline
5 INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FABRY FRANCHISE Galafold ® (migalastat) Fabry Gene Therapy Next - Generation Chaperone POMPE FRANCHISE AT - GAA (cipaglucosidase alfa + miglustat) Pompe Gene Therapy OTHER CLN3 Batten Disease Gene Therapy Next - Generation Re
Slide 6: Positioned for Significant Value Growth
6 Positioned for Significant Value Growth Focused on Execution and Driving Sustainable Double - digit Revenue Growth on Path to Profitability Continue to bring Galafold ® to as many patients as possible, sustain double - digit revenue growth Successful launch of AT - GAA for people living with Pompe
Slide 7: Galafold (migalastat)
7 Galafold® (migalastat) Continued Growth … building a leadership position in the treatment of Fabry disease
Slide 8: Global Fabry Market
8 Global Fabry Market ▪ Fabry Disease is believed to be significantly underdiagnosed – Newborn screening studies suggest Fabry could be one of the more prevalent human genetic diseases (~1:1,000 to ~1:4,000 incidence) ▪ In 2021, Galafold was the fastest growing medicine for Fabry disease and the gre
Slide 9: Galafold Success
9 Galafold Success (as of June 30, 2022) Building on Galafold’s Success and Leveraging Leadership Position to Drive Continued Growth Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable variant. The most common adverse re actions reported with Galafold (≥10%)
Slide 10: Galafold Performance 1H22
10 Galafold Performance 1H22 Reported Revenue Growth of +10.9% to $159.4M - Operational Growth of +17.8% at CER ▪ Global 3 - month net new patients trend greater than 6 - month and 12 - month ▪ In the U.S., the month of June saw highest net new patients and PRFs since April 2021 ▪ Global mix of swit
Slide 11: Galafold Growth Opportunity
11 Penetration of the diagnosed untreated population Increase in newborn screening and diagnostic initiatives Strong IP rights, including COM protection through 2038 Continued penetration into existing markets Expansion into new geographies Broadening of labels Galafold Growth Opportunity $1B Annual
Slide 12: Galafold Initiatives
12 Galafold Initiatives Building the Body of the Evidence around Galafold Broadening Labels: Adolescents and Additional Variants Publications and Medical Presentations Ongoing and Planned Phase IV Studies Over 500 Patients Enrolled in a Global Registry Strengthening our IP Portfolio
Slide 13: Pompe disease therapy (cipaglucosidase alfa + miglustat)
13 AT - GAA (cipaglucosidase alfa + miglustat) … potential to establish a new standard of care for people living with Pompe disease
Slide 14: Pompe Disease Overview
14 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality Estimated inc
Slide 15: An Innovative Approach to Pompe Disease
15 AT - GAA: An Innovative Approach to Pompe Disease Our Scientists Created a Uniquely Glycosylated and Highly Phosphorylated ERT (ATB200) that Significantly Enhances Targeting to Key Affected Muscles ▪ AT - GAA is a two - component therapy combining ATB200, an ERT, with AT2221, an orally administer
Slide 16: Phase 3 PROPEL Study Results: Endpoint Heat Map
16 Phase 3 PROPEL Study Results Primary, Key Secondary and Biomarker Endpoint Heat Map Endpoints Across Motor Function, Pulmonary Function, Muscle Strength, PROs, and Biomarkers Favored AT - GAA over alglucosidase alfa
Slide 17: PROPEL Study Results: Overall Population
17 Phase 3 PROPEL Study Results Overall Population (n=122*) Primary and First Key Secondary Endpoint Showed Greater Improvement with AT - GAA vs. alglucosidase alfa in the Overall Population of ERT - Naïve and ERT - Experienced Patients 6MWD=6 - minute walk distance;; FVC=forced vital capacity; SE=s
Slide 18: PROPEL Topline Results: ERT Experienced Population
18 Phase 3 PROPEL Topline Results: ERT Experienced Population (n=95) ERT Experienced Patients Treated with AT - GAA Demonstrated Improvements over Time in 6MWD and Stabilization over Time in FVC Versus alglucosidase alfa NOTE: Baseline is Mean (STDEV); CFBL is Mean (SE); P - values are nominal 2 - s
Slide 19: PROPEL Study Publication
19 Phase 3 PROPEL Study Publication Clinically Meaningful Outcomes from Phase 3 PROPEL Study Provide the Basis for Global Regulatory Submissions of AT - GAA ▪ Peer - reviewed results from PROPEL suggest that treatment with AT - GAA provided clinically meaningful improvements over standard of care, i
Slide 20: Long-Term Data from Phase 1/2 Clinical Study
20 Long - Term Data from Phase 1/2 Clinical Study (ATB200 - 02) Persistent and Durable Improvements in Motor and Respiratory Function and Reductions in Biomarkers of Muscle Damage and Disease Substrate Observed in Patients out to 36 Months NOTE: * One patient in the ERT - naïve cohort experienced a
Slide 21: Global Pompe Market
21 Global Pompe Market Global Pompe Disease Market Growth Continues to be Driven by the Diagnosis of New Patients - Only One Approved Therapy on the Market up until 2021 ▪ Pompe Disease believed to be significantly underdiagnosed – Newborn screening studies suggests Pompe to be more prevalent than m
Slide 22: Key Takeaways
22 AT - GAA: Key Takeaways ▪ U.S. Regulatory status update: – U.S. PDUFA date 2H2022 1 subject to completion of a manufacturing inspection, which has not yet been scheduled – Negotiations substantially complete for draft label ▪ International Regulatory status update: – CHMP opinion expected 4Q2022
Slide 23: Launch Preparations
23 AT - GAA Launch Preparations Experienced and Passionate Rare Disease Medical and Commercial Organization Poised for Second Successful Launch Key Strengths Commitment to patient access Clear focus on launch Identification of key Pompe disease treatment centers Development of educational materials
Slide 24: Financial & Operational Strategy
24 Financial & Operational Strategy … maintaining a strong financial outlook
Slide 25: Revenue Performance
25 Revenue Performance Q2 Revenue Growth of +4.3% to $80.7M resulting from Strong Operational Growth of +12.9% at CER Offset by Negative FX impact of - 8.6% $77.4M $80.7M - 8.6% +12.9% 2Q21 Operational Growth FX Impact 2Q22 Year - over - Year Sales Growth ▪ Significant currency exposure as 66% of Ga
Slide 26: Financial Outlook and Path to Profitability
Financial Outlook and Path to Profitability Clear Strategy to Build Our Business, Advance Our Portfolio, and Achieve Profitability 26 Sustain Galafold Revenue Growth Deliver on Financial Goals Secure Approvals of AT - GAA $159.4M 1H2022 revenue, +17.8% YoY Operational Growth 2022 Galafold revenue gu
Slide 27: True Measure of Success: Impacting the Lives of Patients
27 True Measure of Success: Impacting the Lives of Patients Living with Rare Diseases YE17 2023+ Thousands of Patients* >1,900+ Patients* YE21 >350 Patients* *Clinical & commercial, all figures approximate
Slide 28: Thank You
| @ ay eee fer AMICUS / 7 } r j A Therapeutics Thank You
Slide 29: Appendix
| @ ay eee fer AMICUS / 7 } r j A Therapeutics Appendix
Slide 30: Environmental, Social, & Governance (ESG) Snapshot
30 Environmental, Social, & Governance (ESG) Snapshot Board of Directors Eco - friendly decision - making has unearthed economic efficiencies while continuing to bolster our standing as a good corporate citizen. Committed to ongoing Board refreshment and diversity of background, gender, skills, and
Slide 31: Reconciliation of Non-GAAP Financial Measures
Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Total operating expenses - as reported GAAP S$ 133,147 S$ 107,867 $ 279,619 $220,785 Research and development: Share-based compens
Amicus Therapeutics — Investor Presentation (September 2022) on 6ix